U.S. Markets closed

Insmed price target raised to $30 from $22 at Leerink

Leerink raised its price target for Insmed shares to $30 saying it continues to be "very encouraged" by the 11 culture conversions observed in Arikayce for the treatment of non-tuberuclous mycobacteria. The firm reiterates an Outperform rating on the stock following the company's conference call.